Tandem Diabetes (TNDM) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $310M

Market Cap: $1.2BFounded: 2006HQ: San Diego, United States

Sector Ranking#43 in Drug Delivery & Formulation #50 in Digital Health & Biotech SaaS

Overview

Tandem Diabetes Care has established itself as a formidable innovator in the diabetes technology sector by pioneering a 'software-first' approach to insulin pump design. Its core strategy revolves around its interoperable t:slim X2 and Tandem Mobi hardware platforms, enhanced by the predictive Control-IQ+ algorithm, creating a sticky ecosystem for users. The company's mission is to leverage smart technology and deep user empathy to create new possibilities and improve the lives of people with diabetes, their loved ones, and healthcare providers.

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Technology Platform

An integrated platform combining software-updatable insulin pump hardware (t:slim X2, Tandem Mobi) with the predictive Control-IQ+ hybrid closed-loop algorithm, designed for interoperability with leading continuous glucose monitors (CGMs).

Funding History

5

Total raised:$310M

IPO$100MUndisclosedNov 7, 2013

Series D$95MVersant VenturesJun 15, 2012

Series C$65MVersant VenturesDec 15, 2010

Series B$40MVersant VenturesJun 15, 2009

Opportunities

Significant growth is driven by the expanding type 2 diabetes indication, the global rollout of the discreet Tandem Mobi system, and the ongoing conversion of patients from multiple daily injections to automated insulin delivery.

Continued software updates enhance product value without new hardware purchases, strengthening customer loyalty.

Risk Factors

Faces intense competition from tubeless pump systems (Insulet) and the integrated Medtronic ecosystem.

Execution risk on key initiatives like iOS compatibility for Mobi and potential supply chain disruptions for critical components.

Reliance on third-party CGM partners for interoperability is a strategic dependency.

Competitive Landscape

Competes directly with Medtronic (integrated system) and Insulet (tubeless Omnipod) in the high-growth automated insulin delivery market. Tandem's differentiation lies in its advanced Control-IQ+ algorithm with AutoBolus, hardware interoperability with leading CGMs, and its software-updatable platform, though it must counter the strong consumer preference for tubeless form factors.